DUBLIN–(BUSINESS WIRE)–The “Osteoarthritis – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Osteoarthritis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews the key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 23, 21, 1, 1, 56, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 7 molecules, respectively.
Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic. (Read more…)
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Topics Covered:
Introduction
- Osteoarthritis – Overview
- Osteoarthritis – Therapeutics Development
Osteoarthritis – Therapeutics Assessment
Osteoarthritis – Companies Involved in Therapeutics Development
Osteoarthritis – Drug Profiles
Osteoarthritis – Dormant Projects
- Osteoarthritis – Discontinued Products
- Osteoarthritis – Product Development Milestones
Appendix
Companies Mentioned
- 4P-Pharma SAS
- Abiogen Pharma SpA
- Ablynx NV
- Aclaris Therapeutics Inc
- Adare Pharmaceuticals Inc
- Akaal Pharma Pty Ltd
- AKL Research and Development Ltd
- Algomedix Inc
- Amgen Inc
- Amplicore Inc
- Amzell BV
- Arthrogen BV
- AskAt Inc
- Asta Pharmaceuticals Co Ltd
- Atlanthera
- Aurealis Pharma AG
- Axsome Therapeutics Inc
- Bioiberica SAU
- Bioorg3.14 LLC
- BioStem Technologies Inc
- Bone Therapeutics SA
- BRIM Biotechnology Inc
- CAR-T (Shanghai) Biotechnology Co Ltd
- CarthroniX Inc
- Cells for Cells SA
- CellTex Therapeutics Corp
- Cellular Biomedicine Group Inc
- Chondrogenix Ltd
- Chugai Pharmaceutical Co Ltd
- Cocoon Biotech, Inc.
- Corestem Inc
- Cynata Therapeutics Ltd
- Cytonics Corp
- Daewoong Pharmaceutical Co Ltd
- DNX Biopharmaceuticals Inc
- Dongkook Pharmaceutical Co Ltd
- Eli Lilly and Co
- Ensol Biosciences Inc
- Eternity Bioscience Inc
- Evgen Pharma Plc
- Flexion Therapeutics Inc
- Galapagos NV
- GeneFrontier Corp
- Genequine Biotherapeutics GmbH
- General Regeneratives Shanghai Ltd
- Gwoxi Stem Cell Applied Technology Co Ltd
- Haplnscience Inc
- Histogen Inc
- HSRx Group
- Inception Therapeutics Inc
- InKemia IUCT Group SA
- International Stem Cell Corp
- Kaken Pharmaceutical Co Ltd
- Kang Stem Biotech Co Ltd
- Kolon TissueGene Inc
- Kukje Pharmaceutical Industry Co Ltd
- Levolta Pharmaceuticals Inc
- LG Chem Ltd
- Link Health Group
- Lubris Biopharma
- Luye Pharma Group Ltd
- MDimune Inc
- Medicrinia Co Ltd
- MediPost Co Ltd
- Medivir AB
- Meluha Life Sciences Sdn Bhd
- Merck KGaA
- Meridigen Biotech Co Ltd
- Mesoblast Ltd
- MetrioPharm AG
- Mor Research Applications Ltd
- Nanode Therapeutics Inc
- NeuroBo Pharmaceuticals Inc
- New York R&D Center for Translational Medicine and Therapeutics Inc
- Nordic Bioscience AS
- Novartis AG
- Orbsen Therapeutics Ltd
- OrthoTrophix Inc
- Paradigm Biopharmaceuticals Ltd
- Peptinov SAS
- Personalized Stem Cells Inc
- Pfizer Inc
- Philogen SpA
- PhytoHealth Corp
- Plakous Therapeutics Inc
- Progenitor Therapeutics Ltd
- ProteoThera Inc
- Regeneus Ltd
- Regenosine Inc
- Regulaxis SAS
- Ribomic Inc
- Rottapharm Biotech Srl
- Samumed LLC
- Sclnow Biotechnology Co Ltd
- Seikagaku Corp
- Serene LLC
- Shionogi & Co Ltd
- SL Bigen Inc
- Steminent Biotherapeutics Inc
- Stempeutics Research Pvt Ltd
- Synartro AB
- Synerkine Pharma BV
- Synokem Pharmaceuticals Ltd
- Taiwan Bio Therapeutics Co Ltd
- Traverse Biosciences Inc
- Unicocell Biomed Co Ltd
- Unity Biotechnology Inc
- WEX Pharmaceuticals Inc
- WNT Scientific LLC
- Xalud Therapeutics Inc
- Xintela AB
- Yooyoung Pharm Co Ltd
- Zimmer Biomet Holdings Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dfhopr
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900